Artemis Hospitals

artemishospitals.com

Artemis Hospitals is a healthcare venture, launched in 2007, by the promoters of the Apollo Tyres Group. Artemis is the first hospital in Gurgaon to be accredited by JCI and NABH. Designed as one of the most advanced in India, Artemis provides an in-depth expertise in the sphere of advanced medical & surgical interventions, comprehensive mix of inpatient and outpatient services. Artemis aims to provide excellent medical care in a compassionate environment and a practice dedicated to pioneering research, empowering the health care professionals and the diverse communities we serve. The clinical procedures followed in the hospital are technologically advanced and supervised by distinguished doctors of international repute. Our endeavor to deliver standard-setting medical care is lead by the needs of the patient; our exceptional medical facilities and unmatched responsiveness has made us one of the most revered hospitals in the country.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

VIRPAX PHARMACEUTICALS ENTERS INTO CRADA WITH THE U.S. ARMY INSTITUTE OF SURGICAL RESEARCH

Virpax® Pharmaceuticals, Inc. | May 06, 2022

news image

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement with the U.S. Army Institute of Surgical Research to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the woun...

Read More

Business Insights, PHARMACY MARKET

OM1 UNVEILS PATENTED, AI-POWERED PLATFORM TO ACCELERATE PERSONALIZED MEDICINE

businesswire | April 17, 2023

news image

OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated using OM1’s longitudinal health history datasets, PhenOM uses AI to identify unique digital phenotypes associated with conditions and outcomes and compare patients’ records to them to highlight risks and opportunities. PhenOM powers personalized healthcare insights at ...

Read More

GLOBAL ASEPTIC PACKAGING FOR THE PHARMACEUTICAL MARKET COMPETITIVE LANDSCAPE OUTLOOK TO 2025

Fashion Trends Now | April 09, 2020

news image

The research report on “Global Aseptic Packaging for the Pharmaceutical Market” serves in-depth analysis on latest and upcoming market scenario of Aseptic Packaging for the Pharmaceutical in the appraisal period, 2020-2025. The report survey Aseptic Packaging for the Pharmaceutical market growth past, sales channel, players profiled in Aseptic Packaging for the Pharmaceutical industry, product type and application market share and Aseptic Packaging for the Pharmaceutical regional sco...

Read More

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

news image

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More
news image

Business Insights

VIRPAX PHARMACEUTICALS ENTERS INTO CRADA WITH THE U.S. ARMY INSTITUTE OF SURGICAL RESEARCH

Virpax® Pharmaceuticals, Inc. | May 06, 2022

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement with the U.S. Army Institute of Surgical Research to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the woun...

Read More
news image

Business Insights, PHARMACY MARKET

OM1 UNVEILS PATENTED, AI-POWERED PLATFORM TO ACCELERATE PERSONALIZED MEDICINE

businesswire | April 17, 2023

OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated using OM1’s longitudinal health history datasets, PhenOM uses AI to identify unique digital phenotypes associated with conditions and outcomes and compare patients’ records to them to highlight risks and opportunities. PhenOM powers personalized healthcare insights at ...

Read More
news image

GLOBAL ASEPTIC PACKAGING FOR THE PHARMACEUTICAL MARKET COMPETITIVE LANDSCAPE OUTLOOK TO 2025

Fashion Trends Now | April 09, 2020

The research report on “Global Aseptic Packaging for the Pharmaceutical Market” serves in-depth analysis on latest and upcoming market scenario of Aseptic Packaging for the Pharmaceutical in the appraisal period, 2020-2025. The report survey Aseptic Packaging for the Pharmaceutical market growth past, sales channel, players profiled in Aseptic Packaging for the Pharmaceutical industry, product type and application market share and Aseptic Packaging for the Pharmaceutical regional sco...

Read More
news image

Business Insights

ELLIPSES PHARMA AND SUNROCK BIOPHARMA ENTER INTO A LICENSING AGREEMENT FOR A FIRST-IN-CLASS BIFUNCTIONAL HER3:TRAIL FUSION PROTEIN

SunRock Biopharma S.L | May 26, 2022

SunRock Biopharma S.L. a biopharmaceutical company that is developing a portfolio of innovative bispecific antibodies to treat incurable cancer, and Ellipses Pharma Limited a global drug development company focused on accelerating the development of new oncology treatments, announce that they have entered into an exclusive licensing agreement for SRB22, a fully human bifunctional HER3:TRAIL fusion protein, which going forward will be known as EP0017. Under the agreement, Ellipses ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us